chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Pain
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 56-year-old (non-pregnant) female patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 56, via an unspecified route of administration, on an unknown date, single dose, for COVID-19 immunisation. Medical history included asthma and COVID-19. The patient has no known allergies to food, medications or other products. The patient received unspecified medication within two weeks of vaccination. Prior to vaccination, patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On Feb 23, 2021, patient felt worse than she did when she had COVID for 3 weeks. She had extreme body aches, headaches, brain fog and extreme tiredness. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures taken as a result of the events included treatment with prednisone from an unknown date. Since the vaccination, patient has not tested for COVID-19. The outcome of the extreme body aches, headaches, brain fog and extreme tiredness resolved with lasting effects on an unknown date in 2021. No follow-up attempts required. Information about batch/lot number cannot be obtained. No further information expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Upper-airway cough syndrome
Clinical narrative: Post-nasal drainage which started within 5 minutes of shot. Do not have allergies. Has continued over the last 24 hours. May be slightly better. No difficulty with deep breathing or swallowing.; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 09:15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient did not take any concomitant medications. On 18Apr2021 at 09:15, the patient experienced post-nasal drainage which started within 5 minutes of shot. Did not have allergies. Had continued over the last 24 hours. Might be slightly better. No difficulty with deep breathing or swallowing. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event post-nasal drainage which started within 5 minutes of shot was not recovered at the time of report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Hypersomnia, Lethargy, Lymphadenopathy
Clinical narrative: Extremely swollen lymph nodes; Body aches; Lethargy; Over sleeping; Trouble staying awake; Headaches; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the right arm on 15Apr2021 at 15:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included paroxetine hydrochloride (PAROXETINE HCL) and calcium carbonate (MANUFACTURER UNKNOWN), both taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 25Mar2021 at 16:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 04:00, the patient experienced extremely swollen lymph nodes, body aches, lethargy, over sleeping, trouble staying awake, headaches and dizziness. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extremely swollen lymph nodes, body aches, lethargy, over sleeping, trouble staying awake, headaches and dizziness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Somnolence
Clinical narrative: Extremely swollen lymph nodes; Body aches; Lethargy; Over sleeping; Trouble staying awake; Headaches; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the right arm on 15Apr2021 at 15:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included paroxetine hydrochloride (PAROXETINE HCL) and calcium carbonate (MANUFACTURER UNKNOWN), both taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 25Mar2021 at 16:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 04:00, the patient experienced extremely swollen lymph nodes, body aches, lethargy, over sleeping, trouble staying awake, headaches and dizziness. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extremely swollen lymph nodes, body aches, lethargy, over sleeping, trouble staying awake, headaches and dizziness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Pain, Pyrexia
Clinical narrative: Extreme fatigue; Aches; Chills; Low grade fever; Dizziness; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 15Apr2021 at 11:30 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis, heart disease, arthritis and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included teriflunomide (AUBAGIO), hydrochlorothiazide,losartan potassium (LOSARTAN HCTZ), escitalopram (MANUFACTURER UNKNOWN) and baclofen (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 13:00, the patient experienced extreme fatigue, aches, chills, low grade fever, dizziness and injection site soreness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fatigue, aches, chills, low grade fever, dizziness and injection site soreness was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Extreme fatigue; Aches; Chills; Low grade fever; Dizziness; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 15Apr2021 at 11:30 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis, heart disease, arthritis and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included teriflunomide (AUBAGIO), hydrochlorothiazide,losartan potassium (LOSARTAN HCTZ), escitalopram (MANUFACTURER UNKNOWN) and baclofen (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 13:00, the patient experienced extreme fatigue, aches, chills, low grade fever, dizziness and injection site soreness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fatigue, aches, chills, low grade fever, dizziness and injection site soreness was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Diarrhoea, Fatigue, Headache
Clinical narrative: Arm pain in injected arm; Headache; Chills; Joint pain; Tiredness; Fever; Diarrhea; Irritability; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 13:00 (at the age of 47-year-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure and various eye conditions requiring medication. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included amlodipine besilate (NORVASC) and bromfenac sodium (PROLENSA); both for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 13:15, the patient had arm pain in injected arm, headache, chills, joint pain, tiredness, fever, diarrhea and irritability. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm pain in injected arm, headache, chills, joint pain, tiredness, fever, diarrhea and irritability was recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Irritability, Pain in extremity, Pyrexia
Clinical narrative: Arm pain in injected arm; Headache; Chills; Joint pain; Tiredness; Fever; Diarrhea; Irritability; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 13:00 (at the age of 47-year-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure and various eye conditions requiring medication. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included amlodipine besilate (NORVASC) and bromfenac sodium (PROLENSA); both for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 13:15, the patient had arm pain in injected arm, headache, chills, joint pain, tiredness, fever, diarrhea and irritability. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm pain in injected arm, headache, chills, joint pain, tiredness, fever, diarrhea and irritability was recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Abdominal pain upper, Arthralgia, Chills, Disorientation
Clinical narrative: Minor fever; Chills; Nausea; A severe pain in stomach/abdomen; A severe pain in stomach/abdomen; Minor body pain on the second day, severe body pain/fatigue the third day; Minor body pain on the second day, severe body pain/fatigue the third day; Disorientation; Joint/muscle pain; Joint/muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 14Apr2021 at 14:00 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications included paracetamol (ACETAMINOPHEN) and occasional salbutamol (ALBUTEROL) inhaler; both for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15Apr2021, the day after, the patient experienced disorientation. On 16Apr2021 at 18:00, on the second day, the patient experienced minor body pain. On 17Apr2021, the third day, the patient experienced severe body pain/fatigue and increased on the fourth (18Apr2021). On 18Apr2021 at 14:00, the patient developed minor fever, chills, nausea, and a severe pain in stomach/abdomen which continued consistently throughout the day until 21:00 (also reported as current time). On an unknown date in Apr2021, the patient still had joint/muscle pain and fatigue, nausea, and chills. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events minor fever, a severe pain in stomach/abdomen was resolved on 18Apr2021 at 21:00 while that of the events disorientation, minor body pain on the second day, severe body pain/fatigue the third day, joint/muscle pain, nausea and chills was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Nausea, Pain, Pyrexia
Clinical narrative: Minor fever; Chills; Nausea; A severe pain in stomach/abdomen; A severe pain in stomach/abdomen; Minor body pain on the second day, severe body pain/fatigue the third day; Minor body pain on the second day, severe body pain/fatigue the third day; Disorientation; Joint/muscle pain; Joint/muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 14Apr2021 at 14:00 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications included paracetamol (ACETAMINOPHEN) and occasional salbutamol (ALBUTEROL) inhaler; both for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15Apr2021, the day after, the patient experienced disorientation. On 16Apr2021 at 18:00, on the second day, the patient experienced minor body pain. On 17Apr2021, the third day, the patient experienced severe body pain/fatigue and increased on the fourth (18Apr2021). On 18Apr2021 at 14:00, the patient developed minor fever, chills, nausea, and a severe pain in stomach/abdomen which continued consistently throughout the day until 21:00 (also reported as current time). On an unknown date in Apr2021, the patient still had joint/muscle pain and fatigue, nausea, and chills. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events minor fever, a severe pain in stomach/abdomen was resolved on 18Apr2021 at 21:00 while that of the events disorientation, minor body pain on the second day, severe body pain/fatigue the third day, joint/muscle pain, nausea and chills was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Adnexa uteri pain, Muscle spasms
Clinical narrative: Severe cramping, like when I am on a very heavy day of my period, including right ovary pain.; Severe cramping, like when I am on a very heavy day of my period, including right ovary pain.; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 0162348-18053) via an unspecified route of administration in the left arm on 17Apr2021 at 09:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines, Inflammatory bowel syndrome (IBS) and known allergy to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included rizatriptan (MANUFACTURER UNKNOWN), naproxen (MANUFACTURER UNKNOWN), norethisterone (NORLYDA) and iron supplements (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received thiomersal (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 17:00, the patient experienced severe cramping like on a very heavy day of her period, including right ovary pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe cramping and right ovary pain were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Hyperhidrosis, Nausea, Tinnitus
Clinical narrative: Developed tinnitus; Severe lightheadedness; Nausea; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 29Mar2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included sciatica. The patient had penicillin allergy and egg intolerance. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included curcuma longa (TURMERIC) and multi vitamin (MANUFACTURER UNKNOWN); both taken for unknown indications from unknown dates and unknown if ongoing. On 29Mar2021 at 12:03, about 3 minutes after the first vaccination, the patient experienced initial reaction of severe lightheadedness, nausea and sweating which lasted about 10 to 15 minutes. A few days later, on 01Apr2021, the patient developed tinnitus. She never had it before and it was going on 3 weeks then. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events lightheadedness, nausea and sweating was resolved on 29Mar2021 while that of the event tinnitus was not resolved at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Nausea, Oropharyngeal pain
Clinical narrative: Very sore throat; Chills; Severe exhaustion; Nausea; Fever; Joint pain; This is a spontaneous report from a contactable other healthcare professional, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 17Apr2021 at 15:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included mental illness. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included valproate semisodium (DEPAKOTE), quetiapine fumarate (SEROQUEL), lurasidone hydrochloride (LATUDA), propranolol (MANUFACTURER UNKNOWN) and clonazepam (KLONOPIN), all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 15:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 14:45, the patient experienced very sore throat, chills, severe exhaustion, nausea, fever and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of the events very sore throat, chills, severe exhaustion, nausea, fever and joint pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Very sore throat; Chills; Severe exhaustion; Nausea; Fever; Joint pain; This is a spontaneous report from a contactable other healthcare professional, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 17Apr2021 at 15:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included mental illness. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included valproate semisodium (DEPAKOTE), quetiapine fumarate (SEROQUEL), lurasidone hydrochloride (LATUDA), propranolol (MANUFACTURER UNKNOWN) and clonazepam (KLONOPIN), all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 15:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 14:45, the patient experienced very sore throat, chills, severe exhaustion, nausea, fever and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of the events very sore throat, chills, severe exhaustion, nausea, fever and joint pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Dyspnoea, Fatigue, Hypersomnia
Clinical narrative: Fever; Pain in left side; Chills; Slept for 2 days; Felt very tired; Somewhat trouble breathing whilewith Fever; This is a spontaneous report from a contactable other healthcare professional, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 01Apr2021 at 03:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included buprenorphine hydrochloride (BELBUCA), fluoxetine (MANUFACTURER UNKNOWN) and clonazepam (MANUFACTURER UNKNOWN); all from unknown date, for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 21:00, the patient experienced fever, pain in left side, chills, slept for 2 days and felt very tired. The patient was able to eat and drink during all this time, continued to have a fever off and on and had somewhat trouble breathing while with fever. The patient also reported that she was scheduled for the second dose of the vaccine on 22Apr2021. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 08Apr2021, the patient underwent lab test included body temperature and the result was 102.3 (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as results of events. The clinical outcome of the events fever, pain in left side, chills, slept for 2 days, felt very tired, somewhat trouble breathing while with fever was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Fever; Pain in left side; Chills; Slept for 2 days; Felt very tired; Somewhat trouble breathing whilewith Fever; This is a spontaneous report from a contactable other healthcare professional, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 01Apr2021 at 03:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included buprenorphine hydrochloride (BELBUCA), fluoxetine (MANUFACTURER UNKNOWN) and clonazepam (MANUFACTURER UNKNOWN); all from unknown date, for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 21:00, the patient experienced fever, pain in left side, chills, slept for 2 days and felt very tired. The patient was able to eat and drink during all this time, continued to have a fever off and on and had somewhat trouble breathing while with fever. The patient also reported that she was scheduled for the second dose of the vaccine on 22Apr2021. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 08Apr2021, the patient underwent lab test included body temperature and the result was 102.3 (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as results of events. The clinical outcome of the events fever, pain in left side, chills, slept for 2 days, felt very tired, somewhat trouble breathing while with fever was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Dyspnoea
Clinical narrative: Extreme chest pain; Trouble breathing; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm left on 17Apr2021 at 12:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of the vaccination. On 17Apr2021 at 19:00, the patient experienced extreme chest pain and trouble breathing roughly 7 hours after injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme chest pain and trouble breathing was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Nausea
Clinical narrative: Dizziness and nausea onset 17April. I went to the ER on 22April and there was also a man there with same symptoms and also had the Pfizer vaccine; Dizziness and nausea onset 17April. I went to the ER on 22April and there was also a man there with same symptoms and also had the Pfizer vaccine; This is a spontaneous report received from a contactable consumer (patient).  A male patient of an unspecified age received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number: not reported), at an unknown route at right arm on an unknown date as dose 2, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) on unknown date as dose 1, single for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not received any other medications the patient received within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had dizziness and nausea on 17Apr2021. The patient went to emergency room on 22Apr2021 and there was also a man there with same symptoms and also had the Pfizer vaccine. The patient had not received any treatment for the events. The outcome of events was not recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Chills, Dyspnoea, Fatigue, Headache
Clinical narrative: Headache; Blurry vision; Chills; Shortness of breath; Very tired (been in bed for 2 days); Body aches; Stomach pain; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 20:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN) and bupropion hydrochloride (MANUFACTURER UNKNOWN); both for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took promethazine (PHENERGAN) and experienced drug allergy. On 19Apr2021, the patient experienced headache, blurry vision, chills, shortness of breath, very tired (been in bed for 2 days) body aches and stomach pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache, blurry vision, chills, shortness of breath, very tired (been in bed for 2 days) body aches and stomach pain were resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Vision blurred
Clinical narrative: Headache; Blurry vision; Chills; Shortness of breath; Very tired (been in bed for 2 days); Body aches; Stomach pain; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 20:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN) and bupropion hydrochloride (MANUFACTURER UNKNOWN); both for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took promethazine (PHENERGAN) and experienced drug allergy. On 19Apr2021, the patient experienced headache, blurry vision, chills, shortness of breath, very tired (been in bed for 2 days) body aches and stomach pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache, blurry vision, chills, shortness of breath, very tired (been in bed for 2 days) body aches and stomach pain were resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Feeling abnormal, Headache, Mobility decreased
Clinical narrative: Nausea; Dull persisting headache; Right arm (not the injection arm- but opposite arm) could not be lifted; Fatigue; Fogginess (almost like an overdose reaction where I could not process thoughts); Sinus pressure; Chills; Mild fever; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the arm left on 21Apr2021 at 08:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received an unspecified medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, the patient experienced fogginess (almost like an overdose reaction where the patient could not process thoughts), sinus pressure, right arm (not the injection arm- but opposite arm) could not be lifted, nausea, dull persisting headache, fatigue, chills and mild fever. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fogginess (almost like an overdose reaction where the patient could not process thoughts), sinus pressure, right arm (not the injection arm- but opposite arm) could not be lifted, nausea, dull persisting headache, fatigue, chills and mild fever was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Paranasal sinus discomfort, Pyrexia
Clinical narrative: Nausea; Dull persisting headache; Right arm (not the injection arm- but opposite arm) could not be lifted; Fatigue; Fogginess (almost like an overdose reaction where I could not process thoughts); Sinus pressure; Chills; Mild fever; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the arm left on 21Apr2021 at 08:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received an unspecified medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, the patient experienced fogginess (almost like an overdose reaction where the patient could not process thoughts), sinus pressure, right arm (not the injection arm- but opposite arm) could not be lifted, nausea, dull persisting headache, fatigue, chills and mild fever. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fogginess (almost like an overdose reaction where the patient could not process thoughts), sinus pressure, right arm (not the injection arm- but opposite arm) could not be lifted, nausea, dull persisting headache, fatigue, chills and mild fever was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Neck pain, Vaccination site pain
Clinical narrative: Extreme neck stiffness; Neck pain; Pain in injection site; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration on 20Apr2021 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD), Sjogren's disease and allergy to gluten, wheat and sesame. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 the patient experienced pain in injection site for first two days. On 23Apr2021, on 4th day(as reported), the patient experienced extreme neck stiffness and pain. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in injection site, extreme neck stiffness and pain was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Swelling
Clinical narrative: Swelling in armpits; Swelling in armpits causing painful rash; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Apr2021 at 10:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to gluten and COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). Concomitant medications included duloxetine (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown dates and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 13:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient previously also received morphine (MANUFACTURER UNKNOWN), for unknown indication from an unknown date and experienced drug allergy. On 21Apr2021, the patient experienced swelling in armpits causing painful rash. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of reported events which included treatment with topical hydrocortisone (CORTISOL) cream. The clinical outcome of the events swelling in armpits causing painful rash was recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Myalgia
Clinical narrative: Fever; Body aches; Chills; Headache; Injection site pain; Muscle soreness; Fatigue; Minimal sore throat; Stuffy nose; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 21Apr2021 at 12:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis and fibromyalgia. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC), calcium (MANUFACTURER UNKNOWN), colecalciferol (VITAMIN D3) and ibuprofen (MANUFACTURER UNKNOWN) not 48 hours before; all taken for unknown indications from unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER0735) via an unspecified route of administration in the left arm on 31Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient previously received erythromycin (MANUFACTURER UNKNOWN), clarithromycin (BIAXIN) and experienced drug allergy. On 22Apr2021 at 01:00, the patient experienced fever, body aches, chills, headache, injection site pain, muscle soreness, fatigue, minimal sore throat and stuffy nose. On the same time, the patient underwent body temperature test and the result was found to be less than 102 (unspecified units). The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events fever, body aches, chills, headache, injection site pain, muscle soreness, fatigue, minimal sore throat and stuffy nose were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Nasal congestion, Oropharyngeal pain, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Fever; Body aches; Chills; Headache; Injection site pain; Muscle soreness; Fatigue; Minimal sore throat; Stuffy nose; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 21Apr2021 at 12:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis and fibromyalgia. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC), calcium (MANUFACTURER UNKNOWN), colecalciferol (VITAMIN D3) and ibuprofen (MANUFACTURER UNKNOWN) not 48 hours before; all taken for unknown indications from unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER0735) via an unspecified route of administration in the left arm on 31Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient previously received erythromycin (MANUFACTURER UNKNOWN), clarithromycin (BIAXIN) and experienced drug allergy. On 22Apr2021 at 01:00, the patient experienced fever, body aches, chills, headache, injection site pain, muscle soreness, fatigue, minimal sore throat and stuffy nose. On the same time, the patient underwent body temperature test and the result was found to be less than 102 (unspecified units). The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events fever, body aches, chills, headache, injection site pain, muscle soreness, fatigue, minimal sore throat and stuffy nose were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.